Regeneron Pharma (REGN) Numbers Adjusted at Goldman Sachs

November 6, 2013 1:52 PM EST Send to a Friend
Get Alerts REGN Hot Sheet
Price: $412.97 -3.43%

Rating Summary:
    17 Buy, 11 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 9 | Down: 10 | New: 35
Trade REGN Now!
Join SI Premium – FREE
Goldman Sachs maintained a Buy on Regeneron Pharma (NASDAQ: REGN) and trimmed its price target to $353.00 (from $355.00). 2013-2016 non-GAAP EPS estimates were changed to $7.40/$9.89/$14.35/$16.19 from $7.40/$10.85/$13.20/$15.98.

Analyst Terence Flynn said, "We are updating our EPS estimates to reflect 3Q13 results and trends. We are lowering our 2014 US Eylea sales estimate slightly to $1.88bn from $1.98bn to reflect single digit growth in 1H14 (based on current trends) followed by an acceleration in 2H14, which assumes Eylea receives priority review for DME. Our estimates remain above consensus as we continue to believe that the DME opportunity is an underappreciated market opportunity and long-term growth driver."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $302.32 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Goldman Sachs

Add Your Comment